Cencora (NYSE:COR) Issues Earnings Results

Cencora (NYSE:COR) released its quarterly earnings data on Wednesday. The company reported $3.34 earnings per share for the quarter, topping analysts’ consensus estimates of $3.21 by $0.13, reports. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company had revenue of $79.05 billion for the quarter, compared to analysts’ expectations of $77.68 billion. Cencora updated its FY 2025 guidance to 14.800-15.100 EPS and its FY25 guidance to $14.80-15.10 EPS.

Cencora Stock Performance

COR traded up $2.15 during trading on Friday, hitting $249.91. The stock had a trading volume of 240,361 shares, compared to its average volume of 1,404,620. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. The firm has a market capitalization of $49.24 billion, a P/E ratio of 32.99, a PEG ratio of 1.49 and a beta of 0.44. The company’s 50-day moving average price is $231.77 and its 200 day moving average price is $230.76. Cencora has a twelve month low of $191.11 and a twelve month high of $251.00.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be paid a $0.55 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.88%. The ex-dividend date is Friday, November 15th. Cencora’s payout ratio is currently 29.29%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on COR. Barclays raised their price objective on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday. JPMorgan Chase & Co. raised their price objective on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a report on Wednesday, August 21st. StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Wells Fargo & Company raised their price objective on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday, August 1st. Finally, Evercore ISI lifted their target price on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $271.20.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now directly owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 15.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cencora

Institutional investors have recently made changes to their positions in the stock. New Millennium Group LLC purchased a new stake in shares of Cencora during the 2nd quarter worth $26,000. TCTC Holdings LLC purchased a new stake in shares of Cencora during the 1st quarter worth $29,000. TFO Wealth Partners LLC purchased a new stake in shares of Cencora in the 1st quarter worth about $30,000. LRI Investments LLC purchased a new stake in shares of Cencora in the 1st quarter worth about $31,000. Finally, MFA Wealth Advisors LLC purchased a new stake in shares of Cencora in the 2nd quarter worth about $30,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.